1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Europe Puts Its API Dependence On Asia Under The Microscope

Europe and Asia’s Manufacturing Role Reversal Over 20 Years Is Analyzed

 
• By Akriti Seth

The high concentration of API manufacturers in India and China posing a risk to the European supply chain became the highlight of the discussion among panellists at a recent Medicines for Europe webinar, as possible solutions to reduce the risk of shortages were pitched.

Europe on globe
Regulators and industry stakeholders discuss the security of Europe’s supply chain • Source: Shutterstock

Active pharmaceutical ingredient sourcing and production was the main theme of a recent webinar on supply chain resilience arranged by Medicines for Europe, where panellists discussed where API for European manufacturers comes from. Concerns for the security of European supply chain were evident as participants agreed that “India and China are actively outperforming European businesses.”

“Europe has lost its strong position as an API producer,” said Mundicare CEO Andreas Meiser, pointing out that Europe’s supply...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By Dave Wallace

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Collating data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

More from Business